P012 Innovations in Mohs Surgery
DESCRIPTION
The performance of Mohs micrographic surgery has undergone rapid and substantive advances from the ability to visualize tumor cells with higher specificity and new reconstructive paradigms to ground-breaking technologies that will harness the power of AI. This session will focus on the cutting edge of Mohs surgery's evolution.
LEARNING OBJECTIVES
Identify evolving techniques and technology to more specifically evaluate tumor histology and tumor margins.
Evaluate innovations in and innovative reconstruction techniques in Mohs surgery.
Recognize Mohs based management of unusual and complex tumors
SCHEDULE
4:00 PM
Advances in Immunostains - Beyond Mart 1
Daniel Brian Eisen, MD, FAAD
4:20 PM
Mohs for Unusual Tumors
Sumaira Zareen Aasi, MD, FAAD
4:40 PM
Evolving Technologies in Mohs Surgery
Daniel M. Siegel, MS, MD, FAAD
5:00 PM
Reconstruction - Repairs that make my life easy
Siegrid S. Yu, MD, FAAD
5:20 PM
Reconstruction - New Techniques and Paradigms
Joseph Sobanko, MD, FAAD
5:40 PM
The PROMise of Mohs performance measurement
Marta Jane Van Beek, MD, MPH, FAAD
6:00 PM
What's old is new again - Keeping your patient out of the neurosurgical suite
Brett M. Coldiron, MD, FAAD
6:20 PM
Q&A
SPEAKERS
Sumaira Zareen Aasi, MD, FAAD
Brett M. Coldiron, MD, FAAD
Daniel Brian Eisen, MD, FAAD
University of California, Davis
Howard Wooding Rogers, MD, PhD, FAAD
Daniel M. Siegel, MS, MD, FAAD
Downstate University Medical Center
Joseph Sobanko, MD, FAAD
University of Pennsylvania
Marta Jane Van Beek, MD, MPH, FAAD
University of Iowa Health Care
Siegrid S. Yu, MD, FAAD
University of California, San Francisco
HANDOUTS
SPEAKER DISCLOSURES
Sumaira Zareen Aasi, MD, FAAD
No financial relationships exist with ineligible companies.
Brett M. Coldiron, MD, FAAD
No financial relationships exist with ineligible companies.
Daniel Brian Eisen, MD, FAAD
No financial relationships exist with ineligible companies.
Howard Wooding Rogers, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Daniel M. Siegel, MS, MD, FAAD
Avita – Advisory Board(Honoraria), Consultant(Honoraria); Biofrontera AG – Stockholder(Stock); Caliber Imaging and Diagnostics Inc. – Board of Directors(Stock); Cara Therapeutics – Advisory Board(Honoraria); DermaSensor Inc – Consultant(Honoraria); Elsevier Inc. – Other(Patent royalties or other compensation for Intellectual Property Rights); Feldan Therapeutics – Consultant(Fees); Greenway Therapeutix – Advisory Board(No Compensation Received), Stockholder(Stock); Lazarus Enterprises Inc. – Consultant(Stock Options); Logical Images – Consultant(Stock Options); Medforce Technologies, Inc. – Consultant(Fees); Modernizing Medicine – Advisory Board(Stock); MycoMedica Life Sciences – Advisory Board(No Compensation Received); Novascan – Stockholder(No Compensation Received); Omnilux – Advisory Board(Equipment); Or-Genix, Therapeutics – Board of Directors(Stock Options), Stockholder(No Compensation Received); Plasmend – Stockholder(No Compensation Received); Pulse Biosciences – Consultant(Fees); RaMedical – Stockholder(No Compensation Received); RBC Consultants – Consultant (1099 relationship)(Honoraria); Regeneron – Investigator(Grants/Research Funding), Speaker(Honoraria); Seaspire Skincare – Consultant(Stock Options); SkinVision – Advisory Board(Stock Options); SPC Dermatology – Employee(Salary); Strata Skin Sciences – Consultant(Fees); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); Tetros Group – Advisory Board(No Compensation Received), Stockholder(No Compensation Received); Verrica Pharmaceuticals Inc – Consultant(Fees);
Joseph Sobanko, MD, FAAD
No financial relationships exist with ineligible companies.
Marta Jane Van Beek, MD, MPH, FAAD
No financial relationships exist with ineligible companies.
Siegrid S. Yu, MD, FAAD
No financial relationships exist with ineligible companies.